Management Approaches That Avoid Missed Opportunities for Recovery in Schizophrenia

Christoph Correll, MD, is currently professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. After finishing his general psychiatry residency at the Zucker Hillside Hospital in Glen Oaks, New York, he trained in child and adolescent psychiatry at Schneider Children's Hospital in New Hyde Park, New York.
 
Dr. Correll's research and clinical work focus on the identification, characterization, and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode, and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, and major depression, as well as aggressive spectrum disorders. He further focuses on the risk–benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.
 
Dr. Correll has authored or co-authored more than 300 journal articles and has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders. He is a reviewer for more than 70 peer-reviewed journals and an editorial board member of 11 scientific journals. Dr. Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received more than 30 national and international research awards and fellowships for his work, and he was listed in 2014 by Thompson Reuters as one of "the most influential scientific minds" and top 1% cited scientists in the area of psychiatry.

Peter Haddad MD, FRCPsych, is a consultant in community psychiatry in Salford, United Kingdom, where he works with a community mental health team. He also provides psychiatric input to a Bail Hostel in a project run by the Probation Service and is an honorary reader at the University of Manchester. His clinical and research interests focus on the treatment of affective disorders and schizophrenia. He also has a major interest in teaching, including public education and combatting the stigma associated with mental health problems. He has contributed to several evidence-based treatment guidelines, including the British Association for Psychopharmacology guidelines for depression (2008), bipolar disorder (2009), and schizophrenia (2011). He was a member of the Guideline Development Group for the National Institute for Health and Care Excellence's guidelines for bipolar disorder (2006) and medicines adherence (2009). He is joint editor of a textbook on antipsychotic long-acting Injections and a textbook on adverse syndromes and psychiatric drugs (both published by Oxford University Press).

Peter J. Weiden, MD, is professor of psychiatry at the University of Illinois Medical Center in Chicago. He is a research psychiatrist at Uptown Research Institute, a clinical trials program specializing in new therapies for severe mental illness.
 
Dr. Weiden's career has focused on improving clinical outcomes for patients with schizophrenia. His research centers on bridging psychopharmacology and public health issues in the treatment of schizophrenia, and he has a particular interest in pharmacologic and psychosocial interventions to help patients and clinicians address medication adherence barriers.
 
Dr. Weiden earned his BA in chemistry from Swarthmore College in Pennsylvania and his MD from the State University of New York at Stony Brook. He completed his psychiatric residency at the Payne Whitney Clinic–New York Hospital and a psychiatric epidemiology fellowship at the Mailman School of Public Health at Columbia University.